[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"carotid-arteriosclerosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:carotid-arteriosclerosis":36},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,66,92,124],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":37,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":65},"100635761","clinical-impact-of-using-improve-to-select-patients-for-carotid-revascularisation-100635761",false,"NCT07556887","Clinical Impact of Using IMPROVE to Select Patients for Carotid Revascularisation","Clinical Impact of the Use of IMPROVE for Selection of Patients for Carotid Revascularisation: a Randomized Controlled Multicentre Non-inferiority Trial in Symptomatic Patients With 30-99% Carotid Stenosis","IMPROVE","Inclusion Criteria:\n\n* Mentally competent\n* 18 years or older\n* Recent (\\\u003C30 days) stroke (modified Rankin scale ≤3) or TIA\n* Ipsilateral 30-99% atheromatous stenosis at the carotid bifurcation assessed using non-invasive imaging according to NASCET criteria\n* Life expectancy \\>5 years\n* Patient and stenosis are suitable for carotid revascularisation\n* Patient is agreeable to randomisation and willing to accept either IMPROVE-based or CAU-based selection method for carotid revascularisation\n\nExclusion Criteria:\n\n* Cardiac source of embolism\n* Carotid stenosis caused by non-atherosclerotic disease e.g. dissection, fibromuscular disease or neck radiotherapy.\n* MRI contra-indications\n* Pregnancy","ALL","18 Years",{"count":20,"type":21},613,"ESTIMATED","INTERVENTIONAL",[24],"NA","Narrowing of the carotid artery due to atherosclerosis with an unstable plaque can cause a stroke. Patients with carotid artery disease who have had a TIA or minor stroke and are at high risk of another stroke are often treated with surgery or stenting to remove the plaque. For lower-risk patients, medication alone is the better option, as surgery also carries risks. A new decision method, based on MRI detection of unstable plaques (IMPROVE), can better assess stroke risk and help determine which patients do or do not need surgery. We are investigating whether this method is at least as effective as the standard approach, which mainly considers the degree of narrowing. We expect that this new method will help reduce strokes and lower healthcare costs.\n\nPatients will be followed for several years to compare which method is better for health and costs.",[27,28,29,30,31,32,33,34,35,36],"Carotid Artery Stenosis Symptomatic","Ischemic Cerebral Infarction","Stroke Ischemic","Atheroscleroses","Stroke (CVA) or TIA","Stroke","Intraplaque Hemorrhage","TIA (Transient Ischemic Attack)","Atherosclerosis Cerebral Infarction","Carotid Arteriosclerosis",[38,39,40,41,42,43,44,45,46,47,48,49,50,51,52],"Carotid Artery Stenosis","Transient Ischemic Attack","Ischemic Stroke","Atherosclerosis","Plaque Rupture","Revascularisation","Carotid Endarterectomy","Carotid Artery Stenting","Magnetic Resonance Imaging","Stroke Risk Prediction","Intraplaque hemorrhage","Clinical Decision Support","Randomized Controlled Mulitcentre Trial","Cost-Effectiveness Analysis","Optimal Medical Therapy","RECRUITING","2026-05-12",{"date":56,"type":57},"2026-05-15","ACTUAL",{"date":59,"type":57},"2026-03-31",{"date":61,"type":21},"2031-08-31",{"name":63,"class":64},"Maastricht University Medical Center","OTHER",10,{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":72,"minAge":18,"maxAge":4,"enrollmentInfo":73,"targetDuration":4,"studyType":75,"phases":4,"briefSummary":76,"conditions":77,"keywords":4,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":91},"100614783","the-synergistic-effects-of-menopause-and-hiv-on-cardiovascular-disease-risk-in-women-100614783","NCT07284082","The Synergistic Effects of Menopause and HIV on Cardiovascular Disease Risk in Women","Inclusion Criteria:\n\n* 90 non-pregnant women with HIV (approximately 30 in each menopausal phase) from the San Francisco MWCCS site.\n\nExclusion Criteria:\n\n* Women who are not virally suppressed (HIV RNA \\>200 copies\u002FmL)\n* Women who are not on antiretroviral therapy\n* Women who have a history of hysterectomy or oophorectomy\n* Women who are receiving treatment for active cancer or tuberculosis","FEMALE",{"count":74,"type":21},90,"OBSERVATIONAL","Menopause is associated with the acceleration of many comorbidities, including cardiovascular disease. Whether HIV and menopause together increase cardiovascular disease risk is a key knowledge gap. The goal of this observational study is to address this knowledge gap by looking at the role of menopause on cardiovascular disease risk factors such as insulin resistance, hypertension, hyperlipidemia, and carotid atherosclerosis using previously collected data. The investigators will look at underlying causes for cardiovascular diseases worsening in menopausal women with HIV by looking at the role of increased inflammation in the body and whether this is altered by weight. The investigators achieve this by enrolling participants who are willing to undergo a whole body MRI.",[78,79,80,36,81],"HIV","Menopause","Cardiovascular (CV) Risk","Body Composition","2026-04-20",{"date":84,"type":57},"2026-04-22",{"date":86,"type":57},"2026-04-17",{"date":88,"type":21},"2030-03-01",{"name":90,"class":64},"University of California, San Francisco",1,{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":4,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":99,"targetDuration":4,"studyType":22,"phases":101,"briefSummary":103,"conditions":104,"keywords":107,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":91},"100600976","phase-2-18falf-nota-octreotide-petmri-in-carotid-artery-disease-100600976","NCT07104487","[18F]AlF-NOTA-octreotide PET\u002FMRI in Carotid Artery Disease","An Exploratory Study of [18F]AlF-NOTA-octreotide PET\u002FMRI in Carotid Artery Disease","Inclusion Criteria:\n\n1. Participant is aged over 18 years.\n2. Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedure\n3. CT angiography imaging at baseline should be available as part of routine care\n4. Participant is diagnosed with a recent ischemic stroke or high-risk TIA (ABCD2 ≥ 4) in the carotid artery territory and ≥ 30% carotid artery stenosis. The stroke\u002FTIA has occurred no more than 21 days prior to tracer administration.\n\nExclusion Criteria:\n\n1. Female who is pregnant or breast-feeding\n2. Participants with a cardio-embolic stroke, small vessel stroke or other defined stroke etiology according to the TOAST classification (23)\n3. Participant has a previous or ongoing recurrent or chronic disease at high risk to interfere with the performance or evaluation of the trial, according to the judgment of the investigator\n4. Participants treated with carotid endarterectomy or carotid artery stenting within the past year\n5. Subject has a contra-indication for or cannot tolerate MR scanning\n6. Subject has an impaired renal function estimated glomerular filtration rate (eGFR) \\\u003C 40 ml\u002Fmin\u002F1.73m² (the last known value may not date from more than 3 months prior to the study PET\u002FMR; if not available a blood analysis may be performed as part of the trial)\n7. Concurrent treatment with corticosteroids and\u002For somatostatin analogues\n8. Subject is unwilling or unable to perform all of the study procedures, or is considered unsuitable in any way by the principal investigator",{"count":100,"type":21},24,[102],"PHASE2","This clinical trial aims to evaluate whether \\[¹⁸F\\]AlF-OC PET\u002FMRI can characterize and quantify inflammation in carotid atherosclerotic plaques. The study will assess if tracer uptake in culprit and non-culprit carotid arteries, measured by standardized uptake values (SUV), is associated with future cerebrovascular events. Specifically, it will examine whether \\[¹⁸F\\]AlF-OC uptake predicts the risk of recurrent ipsilateral TIA, amaurosis fugax, stroke, or other vascular complications.\n\nParticipants will undergo \\[¹⁸F\\]AlF-OC PET\u002FMRI and will be followed via telephone interviews at 90 days, 1 year, and 3 years after their initial stroke or TIA.",[31,105,106,36],"Carotid Artery Plaque","Atherosclerosis Cardiovascular Disease",[108,109,41,110,111,112,113,114],"Internal Carotid Artery","Molecular Imaging","Inflammation","PET\u002FMRI","SST2","[18F]AlF-NOTA-octreotide","Stroke\u002FTIA","2025-08-05",{"date":117,"type":57},"2025-08-11",{"date":119,"type":57},"2025-03-18",{"date":121,"type":21},"2029-09",{"name":123,"class":64},"Universitaire Ziekenhuizen KU Leuven",{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":128,"acronym":129,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":131,"enrollmentInfo":132,"targetDuration":134,"studyType":75,"phases":4,"briefSummary":135,"conditions":136,"keywords":139,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":91},"100597346","residual-stenosis-and-restenosis-following-carotid-endarterectomy-with-primary-closure-a-prospective-tracking-study-100597346","NCT07057297","Residual Stenosis and Restenosis Following Carotid Endarterectomy With Primary Closure, A Prospective Tracking Study","RECEPT","Inclusion Criteria:\n\nPatients without matching any of exclusion criteria who underwent cartotid endarterectomy\n\nExclusion Criteria:\n\nAge ≤18 or ≥90 years\n\nPrevious endarterectomy or stenting\n\nUnsuitable vascular anatomy\n\nHigh perioperative risk\n\nContralateral cranial nerve X or XII palsy\n\nHistory of neck irradiation\n\nTandem carotid stenosis or intracranial vascular pathology (e.g., aneurysm or AVM)\n\nAbsence of signed informed consent","90 Years",{"count":133,"type":21},300,"1 Year","This prospective, multicenter observational study aims to evaluate the incidence, timing, and characteristics of residual and recurrent (restenosis) carotid artery stenosis following carotid endarterectomy (CEA) with primary closure. Conducted across several neurosurgical centers in the Czech Republic, the study will include patients undergoing elective CEA who meet standard clinical indications.\n\nParticipants will undergo preoperative CT angiography and follow-up imaging at 30 days and 1 year post-surgery. Residual stenosis is defined as ≥50% luminal narrowing detected within 30 days postoperatively, while restenosis is evaluated at later time points. The study will also assess clinical outcomes such as ischemic stroke, TIA, myocardial infarction, and mortality. The standardized surgical technique and harmonized diagnostic algorithm across all centers aim to provide robust data on the performance and durability of primary closure CEA.",[36,137,138],"Carotid Stenosis","Brain Stroke",[140,41,141,32],"Carotid Artery","Endarterectomy","2025-06-30",{"date":144,"type":57},"2025-07-09",{"date":146,"type":57},"2025-02-01",{"date":148,"type":21},"2027-01-01",{"name":150,"class":64},"Charles University, Czech Republic"]